Clinical trials: Ejection Fraction
Left Ventricular Function Systolic Dysfunction
Global Strain and Mechanical Dispersion May Predict Death and Ventricular Arrhythmias Better Than Ejection Fraction
The aim of the study is to investigate if global strain and mechanical dispersion may predict death and ventricular arrhythmias better than ejection fraction(EF) in patients with myocardial infarction and heart failure regardless…
- Trial name
- NCT02286908
- Where
- 8 sites in Czechia, Norway
- Volunteers
- 3,100 people
- Sponsor
- Oslo University Hospital
Heart Failure With Preserved Ejection Fraction
Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF
RESPOND-HF is a prospective, multi-center, non-significant risk pilot study with cross-over design. The purpose of the study is to investigate if rate adaptive pacing has the potential to provide benefit to HF patients with…
- Trial name
- RESPOND-HF (NCT03160625)
- Testing
- Rate Adaptive Pacing
- Where
- 5 sites in United States
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Reduced Ejection Fraction
VITAL - the Heart Failure With Reduced Ejection Fraction Sub-study
Heart failure affects over 1 million people in the United Kingdom. Approximately 50% have heart failure with reduced ejection fraction (HFrEF), a condition where the heart muscle does not contract properly.
- Trial name
- NCT06534151
- Testing
- CRT implantation
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University College, London
Heart Failure With Normal Ejection Fraction
Flow Regulation by Opening the Septum in Patients With Heart Failure Trial
To investigate the safety and efficacy of a novel atrial flow regulator (AFR) device in patients with heart failure and preserved ejection fraction.
- Trial name
- FROST-HF (NCT03751748)
- Testing
- AFR implantation
- Where
- 3 sites in Canada
- Volunteers
- 230 people
- Sponsor
- Unity Health Toronto
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
The CARDIOPROTECT Trial
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care…
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Trial name
- NCT07654426
- Testing
- Dexrazoxane, Doxorubicin, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Beth Israel Deaconess Medical Center
Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2
Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Cardiovascular Effects.
Heart failure (HF) is among the most common causes of death in patients with type 2 diabetes (T2D). Ketones, 3-hydroxybutyrate (3-OHB), have shown to have beneficial hemodynamics effect in patients with hearth failure with…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2, Ketonemia
- Trial name
- KETO-HFpEF (NCT05236335)
- Testing
- Ketone ester
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Heart Failure, Reduced Ejection Fraction
Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction
Gliflozins have demonstrated a beneficial effect in terms of incident heart failure and related events in patients with or without diabetes.
- Trial name
- ICARD (NCT05420285)
- Testing
- Dapagliflozin
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Failure With Reduced Ejection Fraction, Endothelial Dysfunction
Endothelial Function in Mechanical Circulatory Support
The pathophysiology of HF is highly variable, with overlapping pathogenic mechanisms that complicates any attempt to create a simple and unified conceptual model.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Endothelial Dysfunction, LVAD
- Trial name
- NCT04539093
- Testing
- Exposure of interest - Use of left ventricular assist device (LVAD)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical College of Wisconsin
Heart Failure With Preserved Ejection Fraction (HFpEF)
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days…
- Trial name
- PARAGLIDE-HF (NCT03988634)
- Testing
- sacubitril/valsartan, valsartan
- Where
- 97 sites in United States, Canada
- Volunteers
- 467 people
- Sponsor
- Novartis Pharmaceuticals
Gallbladder
A Parallel Study Evaluating the Effect of A-F Betafood® on Gallbladder and Liver Function.
Gallstone formation is multifactorial: immutable risk factors include genetics and ethnicity, age and being female, and mutable risk factors include obesity, and metabolic syndrome, diet, rapid weight loss, and other conditions…
- Trial name
- NCT01981343
- Testing
- A-F Betafood
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Heart Failure With Reduced Ejection Fraction
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in subjects 18 to 80 years of age with HFrEF…
- Trial name
- NCT04210375
- Testing
- JK07
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure, Left Bundle Branch Pacing
Clinical Efficacy of Early Left Bundle Branch Pacing for Cardiac Resynchronization Therapy
This is a two-center, prospective randomized controlled trial. The aim of this study is to compare the clinical efficacy of early left bundle branch pacing for cardiac resynchronization therapy and guideline-directed medical…
- Trial name
- Early-RESYNC (NCT06126081)
- Testing
- LBBP+GDMT, GDMT
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Heart Failure
PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.
- Trial name
- PARTHENON (NCT02957409)
- Testing
- sacubitril/valsartan
- Where
- 32 sites in Canada
- Volunteers
- 1,009 people
- Sponsor
- Novartis Pharmaceuticals
Non-obstructive Hypertrophic Cardiomyopathy
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2…
- Trial name
- MAVERICK-HCM (NCT03442764)
- Testing
- mavacamten
- Where
- 32 sites in United States
- Volunteers
- 59 people
- Sponsor
- MyoKardia, Inc.
Magnetic Resonance Imaging, Cardiac Magnetic Resonance Imaging
Evaluation of a Free-breathing Cardiac Cine-MRI Sequence With Image Reconstructions by Deep-Learning in Ischemic Heart Disease
Today, MRI is the gold standard for the precise assessment of left ventricular volume and function, but presents the drawback of having a long acquisition time and of generating motion artifacts, in particular respiratory…
- Conditions
- Magnetic Resonance Imaging, Cardiac Magnetic Resonance Imaging, Deep-Learning, Left Ventricular Ejection Fraction
- Trial name
- CINEDL (NCT05105984)
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Quality of Life
12-week Exercise-based Program in Myocardial Revascularization Subjects
To determine if a 12-week physical exercise program (12-WPEP), after percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) with different left ventricular ejection fraction (LVEF) might improve the…
- Trial name
- NCT03643536
- Testing
- 12-WPEP
- Where
- Colombia
- Volunteers
- 49 people
- Sponsor
- Fundación del Caribe para la Investigación Biomédica
Coronary Artery Disease, Heart Failure With Reduced Ejection Fraction
Resistance Training in Cardiovascular Disease Patients
In this study coronary artery disease patients and patients with heart failure will be randomly assigned to three training groups: combined aerobic interval training with high intensity resistance training, combined aerobic…
- Trial name
- RT in CVD (NCT04638764)
- Testing
- Aerobic interval training combined with high intensity resistance training, Aerobic interval training combined with low intensity resistance training, Aerobic interval training
- Where
- Slovenia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- General Hospital Murska Sobota
Chronic Heart Failure (CHF)
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This study was a multi-center, randomized, double-blind, parallel group, active comparator trial designed to evaluate the overall effect of LCZ696 compared to valsartan on cognitive function as assessed by the CogState…
- Trial name
- PERSPECTIVE (NCT02884206)
- Testing
- LCZ696, Valsartan
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 592 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Reduced Ejection Fraction
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection…
- Trial name
- AWAKE-HF (NCT02970669)
- Testing
- sacubitril/valsartan (LCZ696), enalapril
- Where
- 23 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure with Reduced Ejection Fraction, Chronic Heart Failure
Efficacy of a Streamlined Heart Failure Optimization Protocol
The SHORT trial compares the current standard optimization protocol to a shortened protocol in a randomized control trial.
- Trial name
- SHORT (NCT05021419)
- Testing
- Streamlined protocol, Standard Protocol
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.